Sangamo Therapeutics Inc

Sangamo Therapeutics Inc. is an American clinical-stage biotechnology company headquartered in Brisbane, California, with offices in Richmond California, the UK and France. The firm has a strong focus on genomic medicine and aims to move away from symptom-based treatments and apply cell and gene therapy to combat genetic diseases such as Haemophilia, Sickle Cell Disease, Fabry Disease and Multiple Sclerosis. The firm was founded in 1995. The company’s lead product candidate is SB-525, a gene therapy for the treatment of Haemophilia A. The firm is also developing SAR445136, which is a cell therapy product candidate for the treatment of sickle cell disease. The firm is involved in various partnerships and collaborations with leading global pharmaceutical companies, which include partnering with Pfizer on research into gene therapy aimed at helping patients with Haemophilia. Sangamo Therapeutics Inc. is engaged in research across the spectrum of genomic medicine, including gene and cell therapy clinical research, and pre-clinical programmes in genome engineering and off-the-shelf cell therapy. The firm is developing zinc finger technology, which involves using DNA-binding proteins to control gene expression and cell function. The firm is listed on the NASDAQ under the stock ticker SGMO. Monitor the SGMO share price by adding it to your eToro watchlist.